The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

The National Pharmaceutical Pricing Authority (NPPA) has directed all drug manufacturers and marketers to reduce the Maximum ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

In her budget speech, Finance Minister Nirmala Sitharaman announced the exemption of 36 drugs used to treat cancer, rare diseases, and other severe chronic diseases from the basic customs duty ...

Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...

Enfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy. Enfortumab ...

Moreover, Ryoncil is not definitively preferred over other options after ruxolitinib, such as mycophenolate, sirolimus, and brentuximab vedotin. How preferred Ryoncil is will probably depend on ...

At a median follow-up of about 2.5 years, enfortumab vedotin plus pembrolizumab continued to improve progression-free survival and overall survival. First-line treatment with enfortumab vedotin ...

00001). The 12- and 24-month progression-free survival rates were 51.4% and 37.1% with enfortumab vedotin plus pembrolizumab, versus 21.7% and 12.6% with chemotherapy. The doublet also resulted in a ...

The FDA has approved Pfizer’s supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adults ...